WS
PHIO icon

Wedbush Securities’s Phio Pharmaceuticals PHIO Stock Holding History

Wedbush Securities’s Portfolio PHIO Stock Details PHIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-309
Closed -$73K – 1002
2020
Q2 		$73K Buy
+309
New +$74K 0.01% 883

Other funds holding PHIO

VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wedbush Securities's PHIO Position: Q3 2020 in Review

Wedbush Securities sold out of Phio Pharmaceuticals (PHIO) in Q3 2020, closing a stake of 309 shares — an estimated $73K sold.

Wedbush Securities first reported a position in PHIO in Q2 2020 and held it in 1 quarter. The position peaked at $73K in Q2 2020. 8 funds tracked by Wall St. Rank hold PHIO as of Q3 2020.

  • Wedbush Securities reported no remaining Phio Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Wedbush Securities sold 309 Phio Pharmaceuticals shares in Q3 2020, an estimated $73K.
  • Wedbush Securities first reported a position in Phio Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Wedbush Securities's Phio Pharmaceuticals position peaked at $73K in Q2 2020.
  • 8 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q3 2020.

Based on Wedbush Securities's 13F filing for Q3 2020, filed 20 Oct 2020.